Health Care Resource Use and Costs Pre- and Post-Treatment Initiation With Linaclotide: Retrospective Analyses of a U.S. Insured Population

Douglas Ca Taylor; Jessica L Abel; Tim Bancroft; Paul Buzinec; Alyssa Goolsby Hunter; Robyn T Carson; Carolyn Martin

Health Care Resource Use and Costs Pre- and Post-Treatment Initiation With Linaclotide: Retrospective Analyses of a U.S. Insured Population

Manag Care. 2018 Feb;27(2):33-40.

Authors

Douglas Ca Taylor¹, Jessica L Abel², Tim Bancroft³, Paul Buzinec³, Alyssa Goolsby Hunter³, Robyn T Carson², Carolyn Martin³

Affiliations

¹ Ironwood Pharmaceuticals Inc., Cambridge, Mass.
² Allergan plc, Jersey City, N.J.
³ Optum, Eden Prairie, Minn.

PMID: 29451468

Abstract

As expected, pharmacy costs increased with the introduction of this new treatment in a market dominated by over-the-counter and generic treatments. On the other hand, outpatient GI-related and irritable bowel disease health care resource use and costs substantially decreased among commercial and Medicare patients following linaclotide treatment initiation.

MeSH terms

Adult
Aged
Female
Guanylyl Cyclase C Agonists / administration & dosage
Guanylyl Cyclase C Agonists / economics*
Health Care Costs* / statistics & numerical data
Humans
Insurance Coverage*
Insurance, Health*
Irritable Bowel Syndrome / drug therapy
Male
Middle Aged
Peptides / administration & dosage
Peptides / economics*
Retrospective Studies
United States

Substances

Guanylyl Cyclase C Agonists
Peptides
linaclotide